NCT00999609 used subretinal-injected AAV2-encoded RPE65 to treat retinal dystrophy in 21 patients, where two of the cases showed adverse drug reactions, and one individual showed convulsions [51]. Here, RPE65 is linked to Retinal dystrophy.